IL147731A0 - Peptide pharmaceutical formulations - Google Patents

Peptide pharmaceutical formulations

Info

Publication number
IL147731A0
IL147731A0 IL14773101A IL14773101A IL147731A0 IL 147731 A0 IL147731 A0 IL 147731A0 IL 14773101 A IL14773101 A IL 14773101A IL 14773101 A IL14773101 A IL 14773101A IL 147731 A0 IL147731 A0 IL 147731A0
Authority
IL
Israel
Prior art keywords
pharmaceutical formulations
peptide pharmaceutical
peptide
formulations
pharmaceutical
Prior art date
Application number
IL14773101A
Original Assignee
Bionebraska Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionebraska Inc filed Critical Bionebraska Inc
Priority claimed from PCT/US2001/015872 external-priority patent/WO2001087322A2/en
Publication of IL147731A0 publication Critical patent/IL147731A0/en

Links

IL14773101A 2000-05-19 2001-05-17 Peptide pharmaceutical formulations IL147731A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20526200P 2000-05-19 2000-05-19
PCT/US2001/015872 WO2001087322A2 (en) 2000-05-17 2001-05-17 Peptide pharmaceutical formulations

Publications (1)

Publication Number Publication Date
IL147731A0 true IL147731A0 (en) 2002-08-14

Family

ID=22761491

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14773101A IL147731A0 (en) 2000-05-19 2001-05-17 Peptide pharmaceutical formulations

Country Status (4)

Country Link
EP (1) EP1301200A2 (en)
JP (1) JP2004513069A (en)
AU (1) AU785444B2 (en)
IL (1) IL147731A0 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0306685A (en) 2002-05-21 2005-04-26 Daiichi Suntory Pharma Co Ltd Pharmaceutical composition containing ghrelin
WO2006022301A1 (en) * 2004-08-24 2006-03-02 Daiichi Asubio Pharma Co., Ltd. Liquid preparation of physiologically active peptide
KR100700869B1 (en) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 The stabilized parathyroid hormone composition comprising parathyroid hormone buffer and stabilizing agent
CN103405753B (en) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 Stable insulin secretion accelerating peptide liquid drugs injection pharmaceutical composition
CN107952064B (en) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 Pharmaceutical preparation containing polyethylene glycol lozenges and preparation method thereof
EP3685849A4 (en) * 2017-09-22 2021-12-22 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
CA3167644A1 (en) 2017-09-22 2019-03-28 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety
JP2019060866A (en) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 Method for predicting biokinetics of liquid pharmaceutical composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0383931A (en) * 1989-08-29 1991-04-09 Sumitomo Pharmaceut Co Ltd Low-irritating grf pernasal administration pharmaceutical
UA65549C2 (en) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
ZA9811127B (en) * 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
JP4072319B2 (en) * 1998-03-13 2008-04-09 ノヴォ ノルディスク アクティーゼルスカブ Stabilized water-soluble peptide solution
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition

Also Published As

Publication number Publication date
EP1301200A2 (en) 2003-04-16
AU7483901A (en) 2001-11-26
AU785444B2 (en) 2007-06-14
JP2004513069A (en) 2004-04-30

Similar Documents

Publication Publication Date Title
GB0319041D0 (en) Pharmaceutical Formulations
GB0001621D0 (en) Pharmaceutical compositions
AU6219601A (en) Pharmaceutical compositions
AU8576801A (en) Pharmaceutical compositions
GB0120701D0 (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
GB0121715D0 (en) Pharmaceutical formulations
AU1390002A (en) Pharmaceutical compositions
GB0008485D0 (en) Pharmaceutical compositions
GB2380129B (en) Pharmaceutical formulations
GB0105560D0 (en) Pharmaceutical formulations
HK1045102A1 (en) Pharmaceutical formulations
IL147731A0 (en) Peptide pharmaceutical formulations
AU2001296389A1 (en) Stable peptide formulations
GB0014851D0 (en) Novel pharmaceutical formulation
GB9906126D0 (en) Pharmaceutical formulations
GB9930578D0 (en) Pharmaceutical formulations
GB0014947D0 (en) Novel pharmaceutical formulation
GB0014892D0 (en) Novel pharmaceutical formulation
GB0014883D0 (en) Novel pharmaceutical formulation
IL135442A0 (en) Peptides and pharmaceutical compositions comprising them
GB0124455D0 (en) Pharmaceutical formulations
GB0021487D0 (en) Pharmaceutical
EP1414417A4 (en) Pharmaceutical formulation
IL136274A0 (en) Pharmaceutical compositions comprising vip-related peptides